NCT04281524View on ClinicalTrials.gov

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

October 31, 2021

Conditions
PICC-associated Thrombosis
Interventions
DRUG

CSL312

CSL312 administered as an IV infusion

DRUG

Placebo

Solution of 70% 0.9% saline / 30% CSL312 diluent

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY